Recent 8-K filings for CORT

• July 29, 2026, 4:07 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B

  Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.

• June 17, 2026, 4:36 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected

  Resubmission based on pivotal GRACE trial and Phase III GRADIENT trial data.

• June 3, 2026, 8:00 AM ET litigation materiality 0.60 negative item 8.01

  DOJ declines to intervene in Corcept qui tam lawsuit; relator files amended complaint

  DOJ filed Notice of Election to Decline Intervention on May 19, 2026 in case U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics.

• May 28, 2026, 4:04 PM ET other material materiality 0.55 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×4

  Corcept shareholders approve 8M-share increase to 2024 Incentive Award Plan

  Stockholders approved amendment to 2024 Incentive Award Plan, adding 8,000,000 authorized shares.

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q1 revenue $164.9M (+5% YoY); raises 2026 guidance to $950-1050M; Lifyorli approved

  Revenue $164.9M, up 5% YoY from $157.2M. Net loss $31.8M vs net income $20.5M in Q1 2025 due to launch costs.

• March 25, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer

  Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

• February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B

  Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).

• February 19, 2026, 6:59 PM ET litigation materiality 0.85 negative item 8.01item 9.01

  Federal Circuit affirms Teva generic Korlym does not infringe two Corcept patents

  Court of Appeals for the Federal Circuit found Teva's generic Korlym does not infringe two Corcept patents on safe co-administration with CYP3A4 inhibitors.

• January 22, 2026, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Corcept's ROSELLA Phase 3 trial meets overall survival endpoint; 35% risk reduction

  Relacorilant + nab-paclitaxel reduced risk of death by 35% vs. nab-paclitaxel alone (HR 0.65, p=0.0004).

• December 31, 2025, 6:59 PM ET regulatory materiality 0.78 negative item 8.01item 9.01

  FDA issues Complete Response Letter for Corcept's relacorilant NDA in hypercortisolism

  FDA concluded benefit-risk assessment unfavorable without additional effectiveness evidence.

• November 4, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M

  Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.

• October 14, 2025, 7:59 PM ET other material materiality 0.35 neutral item 1.02item 9.01

  Corcept terminates distribution agreement with Optime Care, effective Jan 8, 2026

  Notice of termination of Distribution Services Agreement with Optime Care given Oct 10, 2025; effective Jan 8, 2026.

• October 6, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01

  Director Gillian Cannon resigns from Corcept board; consulting agreement signed

  Dr. Gillian Cannon resigned from the Board effective October 10, 2025, with no disagreement over operations or policies.

• September 10, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026

  FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.

• July 31, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M

  Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.

• July 14, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  Corcept submits NDA for relacorilant as treatment for platinum-resistant ovarian cancer

  NDA submitted to FDA for relacorilant plus nab-paclitaxel, based on Phase 3 ROSELLA and Phase 2 trials.

• June 16, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07item 9.01

  Corcept shareholders elect nine directors, ratify Ernst & Young, approve executive comp at annual meeting

  All nine director nominees elected with substantial support; David Mahoney received 62.7M for, 14.7M withheld.

• May 5, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates

  Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.

• March 31, 2025, 7:59 PM ET other material materiality 0.95 positive item 8.01item 9.01

  Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly

  30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.

• March 3, 2025, 6:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA accepts Corcept's NDA for relacorilant in Cushing's syndrome; PDUFA Dec 30, 2025

  FDA filed relacorilant NDA for endogenous hypercortisolism (Cushing's syndrome).

• February 26, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M

  Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).

• December 30, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Corcept submits NDA for relacorilant to treat Cushing's syndrome

  NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.

• October 30, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results

  Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.

• July 29, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M

  Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.

• May 23, 2024, 7:59 PM ET other materiality 0.50 neutral item 5.02item 5.07item 9.01

  Corcept Therapeutics shareholders approve 2024 Incentive Award Plan adding 8M new shares

  2024 Plan replaces 2012 plan; total shares authorized = 8M new + 4,073,955 carryover + lapsed awards.

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M

  Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.

• April 17, 2024, 7:59 PM ET other material materiality 0.25 neutral item 1.01item 2.03item 9.01 ◈ Material Agreements

  Corcept subleases 50,632 sq ft in Redwood City from Zuora for six years

  Sublease with Zuora for ~50,632 rentable sq ft at 101 Redwood Shores Pkwy, Redwood City.

• February 15, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M

  Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.

• January 8, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases ×3

  Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback

  Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.

• January 2, 2024, 6:59 PM ET litigation materiality 0.65 negative item 8.01item 9.01

  Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal

  District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.

• December 11, 2023, 6:59 PM ET other material materiality 0.35 neutral item 5.03item 9.01 ◈ Governance Changes

  Corcept amends bylaws to strengthen director nomination and meeting rules

  Board can postpone, reschedule or cancel annual meetings even after notice has been sent to stockholders.

• November 1, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M

  Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.

• August 2, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M

  Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.

• May 24, 2023, 7:59 PM ET other materiality 0.25 neutral item 5.03item 5.07item 9.01 ◈ Shareholder Votes ×5◈ Governance Changes

  Corcept Therapeutics stockholders approve officer exculpation charter amendment at annual meeting

  Stockholders approved amendment to certificate of incorporation to allow officer exculpation under Delaware law.

• May 3, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q1 revenue $105.7M (+13% YoY); raises FY2023 guidance to $435-455M

  Revenue $105.7M vs $93.7M Q1 2022; net income $15.9M ($0.14 diluted EPS) vs $22.8M ($0.20) YoY.

• February 28, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept reports Q4 revenue $103.1M, FY 2022 revenue $401.9M; guides 2023 revenue $430-450M

  Q4 2022 revenue $103.1M vs $98.8M Q4 2021; FY revenue $401.9M vs $366.0M.

• February 13, 2023, 6:59 PM ET litigation materiality 0.65 neutral item 8.01item 9.01

  Corcept reaches preliminary $14M settlement in securities class action; insurer to pay

  Settlement of Melucci v. Corcept case in Northern District of California.

• December 8, 2022, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Corcept settles patent litigation with Hikma; generic Korlym entry set for October 2034

  Settlement with Hikma resolves patent litigation over generic Korlym in District of New Jersey.

• November 3, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M

  Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.

• September 22, 2022, 7:59 PM ET other materiality 0.20 neutral item 1.01

  Corcept extends exclusive specialty pharmacy agreement for Korlym with Optime to March 2024

  Amendment extends Optime's exclusive dispensing services for Korlym to March 31, 2024.

• August 3, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Corcept Q2 revenue $103.4M (up 13% YoY); EPS $0.24; reiterates FY22 revenue guidance

  Revenue $103.4M (Q2 2021: $91.6M); diluted EPS $0.24 vs $0.21.

• June 2, 2022, 7:59 PM ET other material materiality 0.15 negative item 5.07

  Corcept shareholders reject amended 2012 incentive plan at annual meeting

  All nine director nominees elected, with votes ranging from 70.6M to 83.9M in favor.

• May 5, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M

  Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).

• February 15, 2022, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M

  Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).

• December 8, 2021, 6:59 PM ET other material materiality 0.75 negative item 8.01item 9.01

  Corcept wins patent appeal, discloses DOJ subpoena on Korlym sales, extends tender offer to Dec 15

  Federal Circuit affirmed PTAB decision upholding validity of '214 patent (expires 2037) against Teva challenge.

• November 3, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M

  GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.

• August 13, 2021, 7:59 PM ET leadership materiality 0.55 neutral item 5.02item 7.01item 9.01 ◈ executive_change

  Corcept Therapeutics appoints William Guyer as CDO; CMO Andreas Grauer departs

  Andreas Grauer separated as CMO effective Aug 10, 2021, becomes senior medical advisor to assist transition.

• July 29, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M

  Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.72 · Most common event earnings

27 positive 6 negative 15 neutral

source · CORT on sec.gov